The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
Authors: Flowers Christopher R , Link Brian K. , Nastoupil Loretta J. , McDonnell Timothy J. , Kahl Brad S , Vij Kiran R. , Casulo Carla , Friedberg Jonathan W. , Burack Richard , Lossos Izidore S. , Thompson Carrie A. , Yost Kathleen J , Vega Francisco , Syrbu Sergei , Martin Peter , Leonard John P. , Inghirami Giorgio , Bernal-Mizrachi Leon , Mann Karen P. , Allmer Cristine , Lunde Julianne , Maurer Matthew J. , Slager Susan L. , Habermann Thomas M. , Jaye David L. , Feldman Andrew L. , Cerhan James R. 
Published: October 2019

Background: To address the current and long-term unmet health needs of the growing population of patients diagnosed with non-Hodgkin lymphoma (NHL) and NHL survivors, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/) with recruitment at eight centers (Cornell University, Emory University, Mayo Clinic, MD Anderson, University of Iowa, University of Miami, University of Rochester, and Washington University). Here we report on the first two years of enrollment.

Methods: All patients ≥18 years with NHL (exclusive of chronic lymphocytic leukemia) newly diagnosed within 183 days of enrollment are eligible. LEO reviews all pathology diagnoses; annotates and harmonizes all cases with clinical, epidemiologic, pathology and treatment data; builds a NHL tumor bank that includes an H&E slide, a formalin-fixed, paraffin-embedded tissue sample and extracted tumor DNA and RNA; collects peripheral blood and banks DNA, serum, plasma and buffy coat in a central biorepository; and prospectively follows patients regularly to ascertain disease progression/relapse, retreatment, transformation, second cancers, survival, updated exposures, and patient-reported outcomes. We examined the demographics, clinical characteristics, and NHL subtypes for patients enrolled in the first two years (2015-2017) in LEO Cohort and compared these characteristics to population-based registry data from the United States Surveillance, Epidemiology, and End Results (SEER) Program for 2011-2015. We also examined baseline body mass index (BMI), comorbidities and quality of life (QOL) measured with the Functional Assessment of Cancer Therapy - General (FACT-G) scores (0-100 scale) overall and by NHL subtype that were collected in LEO but not available in SEER or any other large, prospective US NHL cohort.

Results: From 2015-2017, LEO enrolled 3244 NHL patients across 47 states (Figure) with a median age at diagnosis of 62 years (range, 18-94 years) and 55.9% male. Based on self-identified race/ethnicity, 85% of the participants were White, 7.4% were Black/African American, 2.6% were Asian, and 3.5% other or more than one race; 9.9% were Hispanic (regardless of race). The most common subtypes were diffuse large B-cell (DLBCL, 33.9%), follicular (FL, 22.2%), mantle cell (MCL, 9.3%), marginal zone (MZL, 8.3%), T-cell (TCL, 10.9%), and all other NHL subtypes (other NHL, 15.3%). These distributions were all within 5% of SEER data, except that 6.8% of participant in LEO were in the age 80+ years group compared to 18.5% in SEER (Table). The overall prevalence of self-reported comorbidities at enrollment was 13.5% for heart disease (range, 12.1% for FL to 16.6% for MCL), 8.8% for diabetes (range, 7.1% for FL to 9.8% for DLBCL), 4.6% for osteoporosis (range, 3.0% for MCL to 6.3% for MZL), and 5.9% for autoimmune disease (range, 2.0% for MCL to 12.6% for MZL). The median BMI was 27.9 kg/m2 (range, 26.7 kg/m2 for TCL to 28.3 kg/m2 for MZL). A total of 2151 participants completed the FACT-G with a median score of 78.7 (range, 75.9 for TCL to 83.3 for MZL). Complete IPI data were available on 2296 participants: 40.4% IPI 0-1, 32.7% IPI 2, 18.3% IPI 3, 8.7% IPI 4-5. Overall, 73.7% of participants were initially treated with systemic therapy (range, 40.0% for MZL and 91.8% for DLBCL); 14.5% were initially managed with observation (range, 1.4% DLBCL and 31.8% for FL); and 2.0% were initially manage with radiotherapy (range, 0.2% for MCL and 3.8% for DLBCL). Outcomes are being prospectively collected.

Conclusions: LEO is a large and diverse cohort of newly diagnosed NHL patients and the first two years of enrollment reflects the broader United States NHL population. Enrollment is ongoing. This unique resource will enable examination of the interactions among a broad array of clinical and molecular factors and their impact on multiple outcomes, to improve prognostication, identify new approaches to improve outcomes and survivorship, and facilitate clinical trials using this infrastructure.

Disclosures

Flowers: Acerta: Research Funding; Pharmacyclics/ Janssen: Consultancy; OptumRx: Consultancy; Janssen Pharmaceutical: Research Funding; V Foundation: Research Funding; Burroughs Wellcome Fund: Research Funding; Spectrum: Consultancy; Eastern Cooperative Oncology Group: Research Funding; Abbvie: Consultancy, Research Funding; Bayer: Consultancy; Millennium/Takeda: Research Funding; Abbvie: Research Funding; Celgene: Research Funding; Gilead: Consultancy; BeiGene: Research Funding; Karyopharm: Consultancy; Denovo Biopharma: Consultancy; Genentech/Roche: Consultancy; Gilead: Research Funding; Genentech/Roche: Research Funding; National Cancer Institute: Research Funding; TG Therapeutics: Research Funding; Pharmacyclics: Research Funding. Nastoupil:TG Therappeutics: Research Funding; Merck: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Janssen: Research Funding; Spectrum: Honoraria; Gilead: Honoraria; Genentech: Honoraria, Research Funding; Karus: Research Funding; Novartis: Honoraria; Juno: Honoraria. Kahl:Acerta: Consultancy; Genentech: Consultancy; Seattle Genetics: Consultancy; Juno: Consultancy; CTI: Consultancy; ADC Therapeutics: Consultancy; Gilead: Consultancy; Celgene: Consultancy; AstraZeneca: Consultancy; Abbvie: Consultancy. Casulo:Celgene: Research Funding; Gilead: Honoraria. Friedberg:Bayer: Honoraria. Lossos:Affimed: Research Funding. Martin:Seattle Genetics: Consultancy; Kite: Consultancy; Janssen: Consultancy; Gilead: Consultancy; Bayer: Consultancy; AstraZeneca: Consultancy. Leonard:Bayer: Consultancy; Celgene: Consultancy; Biotest: Consultancy; United Therapeutics: Consultancy; BMS: Consultancy; MEI Pharma: Consultancy; Juno: Consultancy; Sutro: Consultancy; Karyopharm: Consultancy; ADC Therapeutics: Consultancy; Pfizer: Consultancy; AstraZeneca: Consultancy; Gilead: Consultancy; Genentech/Roche: Consultancy; Novartis: Consultancy. Bernal-Mizrachi:Kodikaz Therapeutic Solutions: Consultancy, Equity Ownership; Takeda Pharmaceutical Company: Research Funding. Maurer:Morphosys: Research Funding; Nanostring: Research Funding; Celgene: Research Funding. Cerhan:Nanostring: Research Funding; Jannsen: Other: Scientific Advisory Board; Celgene: Research Funding.